Home > Oncology > ESMO 2021 > Basic Science & Translational Research > Neutrophils negatively correlate with response to anti-PD-1 monotherapy in dMMR tumours

Neutrophils negatively correlate with response to anti-PD-1 monotherapy in dMMR tumours

Presented By
Dr Laetitia Nebot-Bral, Institute Gustave Roussy, France
Conference
ESMO 2021
Responses to treatment with anti-PD-(L)1 therapy vary across different mismatch repair deficient (dMMR) tumours. Local inhibitory effects of neutrophils were associated with a poor response. Clinical studies have highlighted the efficacy of anti-PD-(L)1 treatment in patients with hypermutated microsatellite instability-high (MSI-H) or dMMR tumours. However, the responsiveness of MSI-H/dMMR tumours to anti-PD-(L)1 treatment is variable. To get more insight in the cause of this variability of response, investigators generated two mouse tumour cell lines inactivated for MSH2 (4T1MSH2-/- and CT26MSH2-/-) to recapitulate the MSI-H/dMMR phenotype. Dr Laetitia Nebot-Bral (Institute Gustave Roussy, France) presented the first results [1]. While anti-PD-1 treatment was effective in the CT26 model, no efficacy was observed in the 4T1 model, even in ultra-mutated 4T1 tumours (>280 mutations/Mb). Unlike the CT26 model, the 4T1...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on